Semaglutide Suppresses Cocaine Use and Dopamine Reward Signaling

Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, providing strong preclinical evidence for GLP-1 drugs in cocaine addiction treatment.

RPEP-09966Animal studyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal study
Evidence
Preliminary Evidence
Sample
N=N/A
Participants
Rats in cocaine self-administration and seeking paradigms

What This Study Found

Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, providing strong preclinical evidence for GLP-1 drugs in cocaine addiction treatment.

Key Numbers

Measured cocaine self-administration, seeking behavior, and dopamine levels in nucleus accumbens. Semaglutide showed superiority over shorter-acting GLP-1 agonists.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, provid
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.
Published In:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 98, 1-10 (2025)
Database ID:
RPEP-09966

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Semaglutide suppressed cocaine taking, seeking behavior, and cocaine-evoked dopamine release, providing strong preclinical evidence for GLP-1 drugs in cocaine addiction treatment.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09966·https://rethinkpeptides.com/research/RPEP-09966

APA

Aranäs, Cajsa; Caffrey, Antonia; Edvardsson, Christian E; Schmidt, Heath D; Jerlhag, Elisabet. (2025). Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 98, 1-10. https://doi.org/10.1016/j.euroneuro.2025.07.001

MLA

Aranäs, Cajsa, et al. "Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.." European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2025. https://doi.org/10.1016/j.euroneuro.2025.07.001

RethinkPeptides

RethinkPeptides Research Database. "Semaglutide suppresses cocaine taking, seeking, and cocaine-..." RPEP-09966. Retrieved from https://rethinkpeptides.com/research/aranas-2025-semaglutide-suppresses-cocaine-taking

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.